Dan Skovronsky
Chief Scientific and Product Officer, Eli Lilly
“In TRIUMPH-1, we saw weight loss approaching bariatric surgery levels at the highest doses, and clinically meaningful efficacy at low doses with only one titration step.”
Dan Skovronsky
One-line summary: Lilly's CSO; the primary first-party voice on retatrutide/TRIUMPH efficacy and the pipeline behind glp1-substitution-to-bariatric-surgery-decline.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
- On glp1-substitution-to-bariatric-surgery-decline:
"In TRIUMPH-1, we saw weight loss approaching bariatric surgery levels at the highest doses, and clinically meaningful efficacy at low doses with only one titration step." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
Sources
Related
Cross-links — fill in.